Sangamo surges 24% after Roche ends development of hemophilia A gene therapy
by
Contributor since / Followers
Contributor since / Followers
4 days ago
Hailshadow/iStock via Getty Images
- Sangamo Therapeutics (NASDAQ:SGMO) rocketed 24% higher after a report that Roche (OTCQX:RHHBY) was ending developmnent of a phase 3 gene therapy candidate for hemophilia A.
- In phase 3, Sangamo has the gene therapy giroctocogene fitelparvovec for the same indication. It is licensed